Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
We pulled three years of CEO cash and equity comp for all 10 public psychedelic companies straight from SEC proxy statements, SEDAR+ circulars, and ASX filings, then checked it against how each stock actually performed. The scatter plot shows almost no correlation at all.
How Clinical Trials Actually Work — and What It Means for the Psychedelic Industry
What does "Phase 3" actually require — how many patients, what counts as a win, who pays for it? We broke down how FDA trials really work, why psychedelics need a different rulebook than a normal pill trial, and where 5-MeO-DMT, psilocybin, LSD, and ibogaine each stand right now.
Eli Lilly Just Paid $3.8 Billion for the Same Molecule People Get From a Toad
Eli Lilly's acquisition of AtaiBeckley centers on a synthetic version of 5-MeO-DMT — the compound underground "Bufo" ceremonies harvest from a wild toad. What the deal signals for the toad, the field, and the science.
Everyone Knows Which Pill They Got. The FDA Just Said What To Do About It.
Functional unblinding is the methodological problem at the centre of psychedelic research. After three years in draft, the FDA's final trial guidance says how sponsors must handle it.
The Clinical Revolution: Psilocybin and 5-MeO-DMT Move from Underground to Evidence-Based Medicine
Rigorous clinical trials are providing what decades of anecdotal evidence couldn't: peer-reviewed data showing these compounds may offer rapid, sustained relief.